McKeage K.,The Warehouse
Drugs | Year: 2014
Ustekinumab (Stelara®) is a human monoclonal antibody that binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, blocking signalling of their cognate receptors. It is established in the treatment of moderate-to-severe plaque psoriasis, but recently received approval in adults with active psoriatic arthritis. Tumour necrosis factor (TNF) inhibitors remain first-line biological agents for the treatment of psoriatic arthritis, but alternative agents are needed. This article summarises the pharmacology of ustekinumab and reviews its use in phase 3 trials in psoriatic arthritis. In these trials, subcutaneous ustekinumab 45 or 90 mg was significantly more effective than placebo, as determined by American College of Rheumatology response criteria at week 24. The drug was also associated with significantly greater efficacy than placebo with regard to secondary endpoints, including the Psoriasis Area and Severity Index ≥75 % response, enthesitis and dactylitis scores, radiographic progression and Health Assessment Questionnaire-Disability Index scores. Response to ustekinumab was maintained during long-term therapy (up to week 100), and was achieved with and without concomitant methotrexate. Ustekinumab was generally well tolerated, and the tolerability profile in psoriatic arthritis was similar to that reported in plaque psoriasis. Throughout long-term ustekinumab treatment, serious infection or major cardiovascular adverse events occurred rarely. More data are needed to clearly define the place of ustekinumab in psoriatic arthritis treatment algorithms. Meanwhile the drug is a valuable additional option for patients with psoriatic arthritis in whom the response to previous non-biological disease-modifying antirheumatic drugs has been inadequate, or for those who have failed anti-TNF therapy. © 2014 Springer International Publishing Switzerland.
Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): A review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts
McCormack P.L.,The Warehouse
Drugs | Year: 2014
Quadrivalent human papillomavirus (HPV) [types 6, 11, 16, 18] recombinant vaccine (Gardasil®; Silgard®) is composed of virus-like particles formed by self-assembly of recombinant L1 capsid protein from each of HPV types 6, 11, 16 and 18. It is indicated for use from the age of 9 years as a two- or three-dose vaccination course over 6 months for the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts caused by the vaccine HPV types. In placebo-controlled trials, quadrivalent HPV vaccine provided high-level protection against infection or disease caused by the vaccine HPV types over 2-4 years in females aged 15-45 years who were negative for the vaccine HPV types, and provided a degree of cross-protection against certain non-vaccine HPV types. The vaccine also provided high-level protection against persistent infection, anogenital precancerous lesions and genital warts caused by the vaccine HPV types over 3 years in susceptible males aged 16-26 years. Protection has been demonstrated for up to 8 years. In subjects who were negative for the vaccine HPV types, high seroconversion rates and high levels of anti-HPV antibodies were observed in females of all age ranges from 9 to 45 years and in males aged 9-26 years. The vaccine was generally well tolerated and was usually predicted to be cost effective in girls and young women. Therefore, quadrivalent HPV vaccine offers an effective means to substantially reduce the burden of HPV-related anogenital disease in females and males, particularly cervical cancer and genital warts. © 2014 Springer International Publishing.
Keating G.M.,The Warehouse
Drugs | Year: 2014
Sofosbuvir (Sovaldi®) is a nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitor that has pangenotypic antiviral activity and a high genetic barrier to resistance. This article reviews the clinical efficacy and tolerability of sofosbuvir in patients with chronic hepatitis C and summarizes its pharmacological properties. Interferon-free treatment with sofosbuvir plus ribavirin achieved high sustained virological response (SVR) rates in treatment-naïve and treatment-experienced patients with HCV genotype 2 or 3 infection, and also had efficacy in patients with HCV genotype 1 infection. Sofosbuvir plus ribavirin was also effective in patients co-infected with HCV and HIV, and sofosbuvir plus ribavirin administered prior to liver transplantation prevented recurrent HCV infection in the majority of patients who had HCV RNA levels below the limit of quantification at the time of transplantation. Sofosbuvir plus peginterferon-α-2a and ribavirin achieved high SVR rates in patients with HCV genotype 1 infection, and also appeared effective in patients with HCV genotype 4, 5 or 6 infection. Oral sofosbuvir was generally well tolerated in patients with chronic hepatitis C. The most commonly reported adverse events and laboratory abnormalities were consistent with those expected with ribavirin and peginterferon-α. In conclusion, sofosbuvir represents an important advance in the treatment of chronic hepatitis C. © 2014 Springer International Publishing Switzerland.
The Warehouse | Date: 2016-09-28
A steering arrangement (1) comprising a baseplate and/or a suspension device, whereupon a first and a second pair of wheels (2) are mounted to rest on an underlying surface. The first pair of wheels has non-steerable wheels, which are mounted in the baseplate and/or suspension device. The second pair of wheels (2) comprises a driven wheel (3), which is steerable around a first vertical axis, and a non-driven wheel (4), which is turnable around a second vertical axis. The non-driven wheel (4) and the driven wheel (3) of the second pair of wheels (2) are mutually coupled through a transmission device (17), which converts a steering movement for the driven wheel (3) to a synchronized steering movement of the non-driven wheel (4).
The Warehouse | Date: 2015-02-24
An industrial truck (1) has a load fork (7) comprising two fork tines (7a, 7b). A load carrier interlocking device (15) is formed by two pivotable cheeks (16a, 16b), each of which is provided with a toothed segment (17a, 17b) on end surfaces facing each other. The toothed segments (17a, 17b) secure the load carrier (L1, L2, L3) positively. The cheeks (16a, 16b) are biased by a spring device (30) toward a pick up position and an interlocking position. When the industrial truck (1) enters a load carrier (L1, L2, L3) with the load fork (7), the cheeks (16a, 16b) are pivoted outwardly away from each other by the load carrier (L1, L2, L3) against the force of the spring device (30). When the load carrier (L1, L2, L3) is completely picked up, the cheeks (16a, 16b) are actuated by the spring device (30) toward the interlocking position, in which the load carrier (L1, L2, L3) is secured positively in position by the toothed segments (17a, 17b).
Agency: GTR | Branch: Innovate UK | Program: | Phase: Smart - Development of Prototype | Award Amount: 250.00K | Year: 2016
There are 35,000 kidney transplant patients in UK (and over 500,000 across developed economies), who have to take immunosuppressant medication for the rest of their lives, in order to avoid graft rejection. Modern immunosupressants have increased 10-year overall kidney graft survival to 60% compared with 40% from a decade prior. However, the narrow therapeutic index and interpatient level variability of immunosuppressants currently necessitates patient monitoring in the clinic. Unfortunately, the burden on the time and cost on both patients and the healthcare system results in infrequent testing, which combined with lifestyle changes and poor medication adherence, leads to immunosuppressant levels being poorly controlled, and concomitantly to shorter graft survival. Considering that the cost benefit of kidney transplantation compared to dialysis is £24,100 per year for each year that the patient has a functioning transplanted kidney, each year of improved graft survival for the ~3,000 new kidney transplants per year in UK would save the NHS £72m per year. To solve this problem, Molecular Warehouse is developing a self-testing diagnostic device for the rapid monitoring of immunosuppressants in kidney transplant patients. The test can be performed at home on the patient’s smartphone, and results immediately sent wirelessly to an online dashboard for review and confirmation by the prescribing doctor. This test will for the first time enable a patient-centric, precision-medicine approach to immunosuppression therapy, improving transplant maintenance and patient quality of life, and reducing operational costs and waiting times in the NHS. After having developed a functional proof of concept of the system, this project will develop the pre-production prototype and initial clinical testing, in collaboration with leading clinicians who have agreed to support this project to make this product available to patients rapidly.
The Warehouse | Date: 2015-09-21
A storage method includes: transmitting request including usage information relating to use of article from service relay server to warehouse management server; transmitting, from warehouse management server to delivery management device, instruction to deliver one-or-more articles packed by user to warehouse; generating detailed information about one-or-more articles in warehouse management server; storing image data obtained by capturing image of one-or-more articles that have been stored, and detailed information in warehouse management server; service relay server transmitting, to user terminal, image data and detailed information acquired from warehouse management server; requesting affiliate server corresponding to usage information to provide optional service for one-or-more articles that have been stored; in response to request from user terminal, requesting warehouse management server to return one-or-more articles that have been stored to user; and requesting by warehouse management server the delivery management device to return one-or-more articles.
The Warehouse | Date: 2016-04-12
A movie theater auditorium is disclosed with reclining or reclined seats, whereby patrons are viewing a screen that is elevated and tilted toward the viewing audience. Comparative to traditional movie theaters with vertical screens with fixed or reclining chairs, exemplary embodiments provide a more natural viewing angle and line of sight for the viewing audience. Some embodiments are disclosed which employ repurposed shipping containers as structural elements of a cinema.
The Warehouse | Date: 2014-03-17
A slot machine game having a first reel having a first set of symbols/indicia thereon, a second reel having a second set of symbols/indicia thereon and a third reel having a third set of symbols/indicia thereon. The first, second, and third reels being operatively configured to spin based upon an initiation button/lever and stop spinning based upon a random generator. The slot machine game being configured to determine a win based upon any three consecutive matching symbols/indicia on the first, second and third reels relative to the adjacent reels.
The Warehouse | Date: 2014-11-03
A computer-implemented method, system, and software product for simultaneously displaying, via a display device, a plurality of product images based on received user selections to allow the user to visualize the appearance of plural products in combination, where at least some of the product images were captured by an image capture device and present products arranged in a non-virtual space.